

## Abstract

[1133] This invention relates to newly identified prostate or prostate cancer related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "prostate cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, and to antibodies that immunospecifically bind these polypeptides, as well as the use of such prostate cancer polynucleotides, antigens, and antibodies for detection, prevention, prognosis, and treatment of disorders of the reproductive system, particularly disorders of the prostate, including, but not limited to, the presence of prostate cancer and prostate cancer metastases. More specifically, isolated prostate cancer nucleic acid molecules are provided encoding novel prostate cancer polypeptides. Novel prostate cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human prostate cancer polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the prostate, including prostate cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.